Unmet Needs in the Management of Acne Vulgaris: A Consensus Statement

June 2023 | Volume 22 | Issue 6 | 582 | Copyright © June 2023


Published online May 5, 2023

Hilary Baldwin MDa, Aaron Farberg MD FAADb, Cheri Frey MDc, Corey Hartman MD FAADd, Edward Lain MDe, Rachel Meltzer MD MPHf, Zoe Draelos MDg

aMedical Director, The Acne Treatment and Research Center, Brooklyn NY, and Clinical Associate Professor of Dermatology, Rutgers Robert Wood Johnson Medical Center, New Brunswick, NJ
bBare Dermatology, Dallas, TX, and Baylor Scott & White Health System, Dallas, TX
cHoward University, Washington, DC
dSkin Wellness Dermatology and University of Alabama at Birmingham Dermatology, Birmingham, AL
eSanova Dermatology, Austin, TX
fBrigham and Women’s Hospital and Harvard Medical School, Boston, MA
gDermatology Consulting Services, High Point, NC

  1. Koltun W, Maloney JM, Marr J, et al. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 ug plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol. 2011;155(2):171-175.
  2. Plewig G, Cunliffe WJ, Binder N, et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception. 2009;80(1):25-33.
  3. Savage LJ, Layton AM. Treating acne vulgaris: systemic, local and combination therapy. Expert Rev Clin Pharmacol. 2010;3(4):563-580.
  4. Radi R, Gold S, Acosta JP, et al. Treating acne in transgender persons receiving testosterone: a practical guide. Am J Clin Dermatol. 2022;23(2):219-229.
  5. Tan J, Del Rosso JQ, Weiss JS, et al. Prevalence and demographics of truncal involvement among acne patients: survey data and a review of the literature. J Clin Aesthet Dermatol. 2022;15(10):62-67.
  6. Dreno B, Thiboutot D, Layton AM, et al. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol. 2015;29(6):1096-1106.
  7. Del Rosso JQ, Bikowski JB, Baum E, et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol. 2007;6(6):597-600.
  8. Kim SA, Kim BR, Chun MY, et al. Relation between pH in the trunk and face: truncal pH can be easily predicted from facial pH. Ann Dermatol. 2016;28(2):216-221. 
  9. Brownstone M. Acne updates. Pearls on treating acne from a recent Maui Derm Conference. Dermatology Times. 2022;43(8). 
  10. Mazzetti A, Moro L, Gerloni M, et al. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563.
  11. Rosette C, Agan FJ, Mazzetti A, et al. Cortexolone 17alpha-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412-418.
  12. Celasco G, Moro L, Bozzella R, et al. Biological profile of cortexolone 17alphapropionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881-886.
  13. Center for Drug Evaluation and Research. US Food and Drug Administration. Accessed May, 2023. https://www.accessdata.fda.gov/drugsatfda_ docs/nda/2020/213433Orig1s000MultidisciplineR.pdf.
  14. Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621-630.
  15. Eichenfield L, Hebert A, Gold LS, et al. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. J Am Acad Dermatol. 2020;83(2):477-485. 
  16. WINLEVI (clascoterone) cream, for topical use [full prescribing information]. Princeton, NJ: Sun Pharmaceutical Industries, Inc.; 2021. 

AUTHOR CORRESPONDENCE

Hilary Baldwin MD HBaldwin@acnetrc.com
Close Menu